Sanofi's Reprehensible Corporate Behavior May Decide Ranitine Cancer Trials
Sanofi will not stand a chance in court if the DOJ determines they were lied to and that the company knew about the inherently unstable nature of ranitidine all along
Tuesday, December 7, 2021 - The science underlying ranitidine being inherently unstable is questionable, at best, but Sanofi's cover-up of the facts and lying to the government may be their undoing. Much has been written about the class action lawsuit potentially involving hundreds of thousands of former Zantac ranitidine users that seek refunds for the cost of the medicine that may have caused them to develop cancer of the stomach, esophagus, bladder, prostate, colon, breast, and other types of cancer. The plaintiffs in the class action also seek reimbursement for the cost of ongoing medical testing that will be required to make sure the cancer is diagnosed as early as possible so that there is the highest likelihood that it can be treated successfully. Sounds reasonable to me. What's most interesting about the case, however, is the nature of the accusations against Sanofi, the maker of Zantac ranitidine, and how the company responded when they first discovered that their product could turn carcinogenic. Lawyers for the class action plaintiffs told Reuters, "They accused the drugmakers of engaging in a decades-long scheme to conceal the dangers and risks associated with Zantac use, despite research that linked ranitidine, the generic name of the drug, to a probable carcinogen, N-nitrosodimethylamine (NDMA). We look forward to holding them accountable, the lawyers said.” Being able to prove that Sanofi knew of the Zantac cancer problem is sure to have an impact on the more than 100,000 Zantac lawsuits that are registered in multidistrict litigation.
Another factor that could influence Zantac heartburn medicine cancer juries is that the US Department of Justice is in the middle of criminally investigating Sanofi over the same issue. The DOJ thinks that Sanofi may have lied to government regulators at the FDA and elsewhere about their knowledge of ranitidine being an inherently unstable molecule and naturally degrading into NDMA under the condition of high heat like what could occur during shipping or retail storage of the capsules. Critics of the theory that ranitidine naturally deteriorates to become NDMA site that there are problems in the overseas drug manufacturing process that could have caused the NDMA spikes. Even the US Food and Drug Administration questions the assertions of online testing pharmacy Valisure whose ranitidine tests concluded NDMA was naturally unstable. "Nitrosamine impurities can be introduced in three ways, with contamination occurring during the manufacturing process or via the supply chain; impurities may also develop because of problems with the drug's stability, according to Jason Rodriguez, director of the division of complex drug analysis at the US Food and Drug Administration's (FDA's) Office of Testing and Research in St. Louis. About 100,000 of the more than 15 million people that were taking Zantac at the time of the April 1, 2020 ranitidine recall, have registered their intent to join the multidistrict litigation and file a lawsuit against Sanofi. Plaintiffs assert that their stomach and other cancer mentioned above was caused by taking Zantac heartburn and acid reflux medicine, regularly and repeatedly.
More Recent Heartburn MedicineLawsuit News:
- Zantac Cancer Trials Are In Discovery To Begin In October 2022 | 7/19/2022
- Zantac Cancer Lawsuits Could Hinge On The Validity of Ranitidine Testing Methods | 7/11/2022
- Zantac Cancer Bellwether Trials In California Could Set The Stage For A Global Settlement Offer | 7/5/2022
- The FDA Recommended Protein Pump Inhibitor Drugs Like Prilosec And Nexium That May Damage Health More Than Zantac | 6/23/2022
- Truck Drivers, Firefighters, and Police Officers May Have Taken More Zantac Than People In Other Occupations | 6/20/2022
Lawyers for Zantac Heartburn Medicine Lawsuits
OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.